>>I agree that Peter's posts are a public service. It is in that vein that I urge him to share his investment decision-making process with even greater clarity, including price targets.<<
I've been thinking about this and have concluded that you are right. Look, Peter starts a valuation thread and has not clarified exactly how to value biopharmaceutical equities with the precision that would allow readers to make money with more certainty. What is up with that? I mean, it's a free country, but there are ethics involved here.
So, I reiterate the call for greater clarity. Please tell us when to buy, what the price targets are, and how to estimate risk precisely for each series of transactions. Also, please provide in-depth analysis of each equity that is being traded. That means none of the usual bs: abstracts and so on. Those don't really help. What we want is a breakdown of the business plan and exit strategies for the business and for short-term valuation plays.
I find Peter's posts too opaque: more quanitification, less qualification. For that matter, SI needs to get its act together, too. SI is not realtime enough. SI needs to provide realtime communication services in the form of instant messaging. This would enable Peter to ping me and everyone else that subscribes to his free service so that we can react to market conditions as they occur.
In fact, the more I write the more ticked off I am getting. I have a good mind to cancel my subscription to Peter's free service.
I'll give it some more thought and get back to the thread.
Yours Truly,
H |
